Tempest Therapeutics Executes Master Services Agreement
Tempest Therapeutics entered into a Master Services Agreement with Factor Bioscience Inc., effective September 22, 2026, to support the development of therapeutic products.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed